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aBStraCt 
Introduction: One of the major problems in health services is the occurrence of healthcare-associated infections (HAIs) by microorganisms 
resistant to various antimicrobials. Objectives: To describe the frequency and susceptibility profile of Pseudomonas aeruginosa and 
Acinetobacter baumannii to carbapenems in the hospital from Fundação Santa Casa de Franca, São Paulo, Brazil. Methods: The 
susceptibility of P. aeruginosa and A. baumannii to carbapenems from 304 clinical isolates between 2007 and 2012 was retrospectively 
analyzed from a microbiology database at the clinical laboratory of the hospital of Fundação Santa Casa de Franca, São Paulo, Brazil. 
Results: From isolated and identified strains, 236 (5.3%) P. aeruginosa were susceptible to imipenem (2007 – 69.6% to 2012 – 41.7%) 
and meropenem (2007 – 63.3% to 2012 – 25%). In addition, all 68 (1.7%) A. baumannii isolates were susceptible to both antibiotics. 
Conclusion: A. baumannii resistance to carbapenems was not identified; however, there was a decrease in susceptibility to carbapenems 
over the years for P. aeruginosa.
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introDuCtion
One of the major problems in health services is the 
occurrence of healthcare-associated infections (HAIs) by 
microorganisms resistant to various antimicrobials. In hospital 
settings, non-fermenting Gram-negative bacilli, such as 
Pseudomonas aeruginosa and Actinobacter baumannii, 
stand out as emerging etiological agents of pneumonia and 
sepsis, with critical patients’ mortality of 27%-48%(1-3).
In this context, carbapenems represent one of the 
therapeutic options for infections against non-fermenting 
Gram-negative bacilli, although they decrease susceptibility(4-6) 
and exhibit a relative stability against most extended-spectrum 
beta-lactamases(ESBL)(7). For this reason, carbapenems are 
frequently used as a last resort in the treatment of nosocomial 
infections caused by Gram-negative bacteria resistant to other 
beta-lactams or antibacterials(2-4, 8).
The exponential growth of bacterial resistance has 
demanded monitoring the results of cultures in clinical samples 
towards the quantitative understanding of antibiotic resistance 
evolution and the conduction of therapeutic interventions(9).
Thus, the objective of this research was to evaluate the 
frequency and the susceptibility profile of non-fermenting 
















This is a retrospective observational study conducted on a 
database at the microbiology sector in the clinical laboratory 
of the hospital of Fundação Santa Casa de Franca, São Paulo, 
Brazil. The study covered the period 2007-2012, yielding a total 
of 4,464 culture results. The project was approved by the Human 
Research Ethics Committee (CAAE: 22484714.6.0000.5393).
Non-fermenting Gram-negative bacilli (P. aeruginosa and 
A. baumannii) were identified by Gram stain and the NF II kit 
(Probac do Brasil, São Paulo, Brazil), which, according to the 
manufacturer, encompasses oxidase tests, capacity of growth 
on MacConkey agar, use of glucose, maltose and lactose into 
oxidation-fermentation (OF) base medium, lysine and arginine 
decarboxylation (Moeller base) and gelatin liquefaction.
Antibiogram was done by disc-diffusion method in Petri 
plates with Mueller Hinton Agar and incubation at 37°C during 
24 h, according to current guidelines for selection criteria and 
cut-off points used for antibiotics – Clinical and Laboratory 
Standards Institute (CLSI)(10).
For data analysis, descriptive statistics was used in absolute 
and relative frequency.
rESuLtS
Among the 4,464 culture results distributed in the years 
2007 (865), 2008 (981), 2009 (485), 2010 (539), 2011 (704) 
and 2012 (890), 236 (5.3%) strains of P. aeruginosa and 68 
(1.5%) of A. baumannii were isolated.
According to the Table, among the isolated and identified 
strains, 236 (5.3%) P. aeruginosa demonstrated greater 
susceptibility to imipenem (2007 – 69.6% to 2012 – 41.7%) 
than to meropenem (2007 – 63.3% to 2012 – 25%). However, 
decreased profiles of susceptibility to carbapenems were 
revealed over the years. Besides, the 68 (1.7%) A. baumannii 
isolates were susceptible to both antibiotics.
DiSCuSSion
In this research, non-fermenting Gram-negative bacilli 
were more susceptible to carbapenems than those reported 
by Somily et al. (2012)(11), which demonstrated susceptibility 
to imipenem and meropenem of 9.5% for A. baumannii 
and 9.1% and 18.2%, respectively, for P. aeruginosa. Other 
works(3, 8, 12) presented different frequencies of susceptibility of 
A. baumannii to carbapenems (32.6%, 69.9% and 59%).
Another study, carried out at a tertiary Brazilian hospital, 
from 1999 to 2008, identified a 3.7-fold increase in the isolation 
frequency of multidrug-resistant Gram-negative bacilli 
(p < 0.001). A. baumannii was the most prevalent bacterium 
(36.2%), with a 4.8-fold increase (p < 0.001), mostly isolated 
at intensive care units (ICU), ranging from 0% to 62.5%. 
On the other hand, regarding the multidrug resistance of 
P. aeruginosa, there was an increase of 23.4% to 64.6%(13).
In the south of Brazil, a research at a small hospital, 
between 2007 and 2009, identified a high frequency of 
multidrug resistance and genetic diversity. Rates of resistance 
to carbapenems were observed in 25% of the P. aeruginosa 
isolates and in 50% of Acinetobacter spp.(14).
Conversely, out of the 158 A. baumannii isolates from 
11 hospitals in New York, 31% were susceptible to meropenem 
(2013-2014), an increase in comparison with the 13% 
observed in 2009 (p < 0.0001). Nevertheless, 481 isolates of 
P. aeruginosa showed increased frequency of susceptibility to 
meropenem: 79% (2013-2014), when in comparison with the 
59% in 2009 (p < 0.0001)(15).
Data about hospitals in Latin America from 2002 to 2013 
demonstrated rates of resistance to carbapenems of up to 66% 
and 90% for P. aeruginosa and A. baumannii, respectively; 
frequencies higher than 50% were reported in several 
countries(16). 
A possible etiology for the increased occurrence of 
carbapenem-resistant P. aeruginosa and A. baumannii in 
Latin America is patient-to-patient transmission, which is also 
responsible for local outbreaks and nosocomial dissemination. 
taBLE − Distribution of Pseudomonas aeruginosa susceptibility profile to 
carbapenems (imipenem and meropenem) at a tertiary hospital in Franca (SP), 




n % n %
2007 55 69.6 50 63.3
2008 30 62.5 27 56.3
2009 12 60 10 50
2010 14 56 11 44
2011 24 46 22 42.3
2012 5 41.7 3 25
Total 140 59.3 123 52.1
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7The permanence of infections by these microorganisms leads to 
the use of broad-spectrum antibiotics, especially carbapenems, 
and increase selective pressure for resistance to these drugs. 
The presence of A. baumannii coincided with the growing use 
of this class of antimicrobial. Although there is no consensus, 
the use of antibiotics can be an independent risk factor for the 
development of P. aeruginosa and A. baumannii resistance to 
carbapenems(13, 17-19).
In this study, from 2007 to 2012, the analysis of 
microbiological culture results allowed concluding that 
P. aeruginosa, identified in 5.3%, was more susceptible 
to imipenem (69.6% in 2007 to 41.7% in 2012) than to 
meropenem, but there was a more accentuated decline of 
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susceptibility to meropenem over the years (63.3% to 25%) – 
Table. A. baumannii presented susceptibility to carbapenems, 
with no alterations in the studied period.
Principally in hospitals, identification of microorganisms 
with epidemiologic value is globally recognized in terms 
of antibiotic susceptibility profile. Clinical complications, 
mortality and the elevated cost associated with infections 
caused by these etiologic agents reinforce the real necessity for 
the implementation of a program of active microbiological 
surveillance in health-care institutions. So, it is essential that 
health professionals and citizens become more and more 
aware and involved in the fight against HAIs, above all against 
increasingly recurrent multidrug-resistant microorganisms.
rESuMo 
Introdução: Um dos grandes problemas nos serviços de saúde é a ocorrência de infecções relacionadas com assistência à saúde 
(IRAS) por microrganismos resistentes a vários antimicrobianos. Objetivos: Descrever a frequência e o perfil de suscetibilidade 
de Pseudomonas aeruginosa e Acinetobacter baumannii aos carbapenêmicos no hospital da Fundação Santa Casa de Franca, São 
Paulo, Brasil. Métodos: Retrospectivamente, a suscetibilidade de P. aeruginosa e A. baumannii aos carbapenêmicos foi analisada 
em 304 isolados clínicos entre 2007 e 2012, a partir de um banco de dados do setor de microbiologia do laboratório clínico do 
hospital da Fundação Santa Casa de Franca, São Paulo, Brasil. Resultados: Das cepas isoladas e identificadas, 236 (5,3%) P. 
aeruginosa eram suscetíveis a imipenem (2007 – 69,6% a 2012 – 41,7%) e meropenem (2007 – 63,3% a 2012 – 25%). Além 
disso, todos os 68 (1,7%) isolados de A. baumannii eram suscetíveis aos dois antibióticos. Conclusão: Não foi identificada resistência 
de A. baumannii aos carbapenêmicos, no entanto houve diminuição da suscetibilidade aos carbapenêmicos no decorrer dos anos 
para P. aeruginosa.
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